Back to Market返回行情

ECOR electroCore, Inc.

USHealthcare
$6.53-17.45%ClosedMarket Cap: $54.2M

As of 2026-07-08 16:00

Why ECOR matters now

electroCore, Inc. (ECOR) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.53 with -17.45% on the session and $54.2M in market capitalization; recent performance reads 1-month +42.55% and YTD +87.64%.

The latest financial table shown here is Q1 2026, with revenue of $9.6M, net income of $-5.3M, and EPS of $-0.59. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.8%.

The latest indexable market news headline is "electroCore, Inc. (ECOR) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript" from Seeking Alpha.

Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Lev Joshua S. filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

-13.26

P/S

2.00

EV/EBITDA

-5.61

DCF Value

$-347.26

FCF Yield

-9.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

87.2%

Operating Margin

-42.0%

Net Margin

-44.1%

ROE

836.3%

ROA

-99.4%

ROIC

-379.1%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$9.6M$-5.3M$-0.59
Q4 2025$9.2M$-3.0M$-0.38
FY 2025$32.0M$-14.0M$-1.65
Q3 2025$8.7M$-3.4M$-0.40

Analyst Ratings

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

Strong Buy: 1Buy: 4Hold: 0Sell: 0Strong Sell: 0
HC Wainwright & Co.Buy
2026-01-26

Trading Activity

Insider Trades

Lev Joshua S.officer: CFO and Interim President
Sell2026-05-29
Errico Thomas J.director
Buy2026-05-26
Errico Thomas J.director
Sell2026-05-26
Lev Joshua S.officer: CFO and Interim President
Sell2026-05-22
Fox Michaelofficer
Sell2026-04-14

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

0.87

electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.